We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Cronos Group (CRON - Free Report) closed at $14.99 in the latest trading session, marking a +0.33% move from the prior day. This change outpaced the S&P 500's 0.65% loss on the day. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Prior to today's trading, shares of the cannabis company had lost 4.9% over the past month. This has lagged the Finance sector's gain of 3.02% and the S&P 500's gain of 4.11% in that time.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be August 8, 2019. Meanwhile, our latest consensus estimate is calling for revenue of $5.64 million, up 114.56% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.03 per share and revenue of $36.74 million, which would represent changes of +137.5% and +204.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRON is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that CRON has a Forward P/E ratio of 560.25 right now. This represents a premium compared to its industry's average Forward P/E of 11.58.
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Gains As Market Dips: What You Should Know
Cronos Group (CRON - Free Report) closed at $14.99 in the latest trading session, marking a +0.33% move from the prior day. This change outpaced the S&P 500's 0.65% loss on the day. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Prior to today's trading, shares of the cannabis company had lost 4.9% over the past month. This has lagged the Finance sector's gain of 3.02% and the S&P 500's gain of 4.11% in that time.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be August 8, 2019. Meanwhile, our latest consensus estimate is calling for revenue of $5.64 million, up 114.56% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.03 per share and revenue of $36.74 million, which would represent changes of +137.5% and +204.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRON is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that CRON has a Forward P/E ratio of 560.25 right now. This represents a premium compared to its industry's average Forward P/E of 11.58.
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.